[go: up one dir, main page]

PE20180458A1 - METHOD AND COMPOSITION AND KIT TO TREAT ERECTILE DYSFUNCTION - Google Patents

METHOD AND COMPOSITION AND KIT TO TREAT ERECTILE DYSFUNCTION

Info

Publication number
PE20180458A1
PE20180458A1 PE2016001554A PE2016001554A PE20180458A1 PE 20180458 A1 PE20180458 A1 PE 20180458A1 PE 2016001554 A PE2016001554 A PE 2016001554A PE 2016001554 A PE2016001554 A PE 2016001554A PE 20180458 A1 PE20180458 A1 PE 20180458A1
Authority
PE
Peru
Prior art keywords
composition
kit
erectile dysfunction
treat erectile
poloxamer
Prior art date
Application number
PE2016001554A
Other languages
Spanish (es)
Inventor
Geraldino Neder
Rafael Padilla
Original Assignee
Fagron B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16177896.4A external-priority patent/EP3266458A1/en
Priority claimed from BR102016015716-1A external-priority patent/BR102016015716A2/en
Application filed by Fagron B V filed Critical Fagron B V
Publication of PE20180458A1 publication Critical patent/PE20180458A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a una composicion farmaceutica que comprende una prostaglandina vasoactiva tal como alprostadil, entre otros y un vehiculo farmaceuticamente aceptable que comprende: a) lecitina; b) palmitato de isopropilo y c) urea, donde dicho vehiculo comprende miristato de isopropilo o un poloxamero, preferiblemente un poloxamero 407 y se formula como una crema con una viscosidad a 25°C de entre 25.000 a 200.000 mPa. Tambien se refiere a un metodo de preparacion, un aplicador y un kit. Dicha composicion es util en el tratamiento de la disfuncion erectil masculinaIt refers to a pharmaceutical composition comprising a vasoactive prostaglandin such as alprostadil, among others, and a pharmaceutically acceptable carrier comprising: a) lecithin; b) isopropyl palmitate and c) urea, wherein said carrier comprises isopropyl myristate or a poloxamer, preferably a poloxamer 407 and is formulated as a cream with a viscosity at 25 ° C of between 25,000 to 200,000 mPa. It also refers to a method of preparation, an applicator and a kit. This composition is useful in the treatment of male erectile dysfunction

PE2016001554A 2016-07-05 2016-08-31 METHOD AND COMPOSITION AND KIT TO TREAT ERECTILE DYSFUNCTION PE20180458A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16177896.4A EP3266458A1 (en) 2016-07-05 2016-07-05 Method and composition and kit for treating erectile dysfunction
BR102016015716-1A BR102016015716A2 (en) 2016-07-05 2016-07-05 METHOD, COMPOSITION AND KIT FOR TREATMENT OF ERECTILE DYfunction

Publications (1)

Publication Number Publication Date
PE20180458A1 true PE20180458A1 (en) 2018-03-05

Family

ID=60331201

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001554A PE20180458A1 (en) 2016-07-05 2016-08-31 METHOD AND COMPOSITION AND KIT TO TREAT ERECTILE DYSFUNCTION

Country Status (3)

Country Link
CL (1) CL2016002181A1 (en)
CO (1) CO2016001336A1 (en)
PE (1) PE20180458A1 (en)

Also Published As

Publication number Publication date
CL2016002181A1 (en) 2017-09-08
CO2016001336A1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
CL2020000220A1 (en) Compositions comprising amino acids for use in the treatment of diseases related to mitochondrial dysfunction.
MX392606B (en) COMPOSITIONS FOR THE CONTROLLED RELEASE OF CYSTEAMINE AND THE SYSTEMIC TREATMENT OF CYSTEAMINE-SENSITIVE DISORDERS.
SV2015005115A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
MX393613B (en) GEL COMPOSITIONS FOR TRANSDERMAL DELIVERY TO MAXIMIZE DRUG CONCENTRATIONS IN THE STRATUM CORNEUM AND SERUM, AND METHODS OF USING SAME.
CL2016002516A1 (en) "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct
PE20140936A1 (en) TRANSDERMAL COMPOSITIONS OF IBUPROFEN AND METHODS OF USE OF THE SAME
AR090349A1 (en) COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS, KIT AND USE
PE20211069A1 (en) COMPOSITION INCLUDING 5'-METHYLSEELENOADENOSINE, SELENOADENOSYL-L-HOMOCYSTEIN AND GLUTAMYL-METHYLSELENOCYSTEINE RANGE
MX2015009772A (en) Spiro-lactam nmda receptor modulators and uses thereof.
CL2019002172A1 (en) Therapeutic agent for liver diseases.
CL2016000008A1 (en) Treatment of inflammatory lesions of rosacea with ivermectin.
MX2018005715A (en) USE OF ANTAGONISTS OF THE EP4 RECEIVER FOR THE TREATMENT OF LIVER CANCER ASSOCIATED WITH NASH.
PE20171622A1 (en) INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION
MX2016006318A (en) 7-BENCIL-4- (2-METHYLBENCIL) -2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A] PIR IDO [3,4-E] PIRIMIDIN-5 (1H) -ONA, SALTS OF THE SAME AND METHODS OF USE.
CR20190144A (en) Aza-indazole compounds for use in tendon and/or ligament injuries
CL2020000221A1 (en) Compositions comprising amino acids for use in the treatment of diseases related to mitochondrial dysfunction.
ECSP19026973A (en) NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA
PE20200600A1 (en) COMPOSITIONS AND METHODS TO PROMOTE HAIR GROWTH WITH MPC INHIBITORS
MX2022001736A (en) Topical formulations and treatments.
CO2019009000A2 (en) Pharmaceutical combinations to treat cancer
AR111374A1 (en) USE OF LIK066 IN PATIENTS WITH HEART FAILURE
MX2015016995A (en) COMPOSITE FORMULATION IN PHARMACEUTICAL CAPSULE THAT INCLUDES TADALAFIL AND TAMSULOSINE.
AR102778A1 (en) PHARMACEUTICAL COMPOSITION, ITS PREPARATION AND ITS USES
MX2020010747A (en) TOPICAL FORMULATIONS COMPRISING STRONTIUM AND METHYLSULPHONYLMETHANE (MSM) AND METHODS OF TREATMENT.
CL2018002200A1 (en) Combined administration of a penetrating agent and a sulfur compound containing compound for plants.

Legal Events

Date Code Title Description
FD Application declared void or lapsed